Abstract
The enzymic cleavage of the terminal sugar residue from the plasma membrane of neoplastic cells by neuraminidase of vibrio cholerae origin causes a marked increase in immunogenicity of most experimental tumors [1–6, 8–16]. In a DBA/2 leukemia L1210 system, a single leukemic cell is capable of producing leukemia and the ultimate death of the host. However, mice which were immunized with neuraminidase-treated leukemia L1210 cells remained protected against a challenge of 100,000 untreated leukemic cells [1–3]. Repeated injections of neuraminidase-treated leukemia L1210 cells reduced the lethality rate and increased survival of mice with leukemia L1210 tumor grafts [15, 16]. Chemotherapy plus neuraminidase-treated L1210 cells administered in a sequence which preserves the host’s immunobiologically competent cells resulted in the cure of a significant portion of immunized mice [4, 7, 9]. The immunoprotection evoked by the stimulation from the neuraminidase-treated tumor cells was specific for the particular tumor and could be transferred by sera or splenic lymphocytes into unimmunized syngeneic mice [5, 7, 15, 16]. Recently, considerable attention has been directed to combined modality therapy in spontaneous Gross virus-induced leukemia in AkR mice because in many respects AkR leukemia has similar characteristics to the human leukemias.
This work was supported by contracts NCI Virus Cancer Program NO1-CP-43879 and NCI Immunotherapy Program NO1-CP-43225.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bagshawe, K. D., Currie, G. A.: Immunogenicity of L1210 murine leukemia cells after treatment with neuraminidase. Nature (Lond) 218, 1254 (1968).
Bekesi, J. G., St. Arneault, G., Holland, J. F.: Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment. Cancer Res. 31, 2130–2132 (1971).
Bekesi, J. G., St. Arneault, G., Walter, L., Holland, J. F.: Immunogenicity of leukemia L1210 cells after neuraminidase treatment. J. Natl. Cancer Inst. 49, 107–118 (1972).
Bekesi, J. G., Roboz, J. P., Walter, L., Holland, J. F.: Stimulation of specific immunity against cancer by neuraminidase-treated tumor cells. Behring Inst. Mitt. 55, 309–321 (1974).
Bekesi, J. G., Roboz, J. P., Holland, J. F.: Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice. Israel J. Med. Sci. 12, 288–303 (1976).
Bekesi, J. G., Holland, J. F., Fleminger, R., Yates, J., Henderson, E. S.: Immunotherapeutic efficacy of neuraminidase-treated allogeneic myeloblasts in patients with acute myelocytic leukemia. In: Control of Neoplasia by Modulation of the Immune System. Chirigos, M. A. (ed.). New York: Raven Press, 1977, pp. 573–592.
Bekesi, J. G., Roboz, J. P., Holland, J. F.: Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia. Annals of N.Y. Acad. Sci. 277, 313–331 (1976).
Breslow, N. A.: Generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometricka 57, 579–594 (1970).
Holland, J. F., Bekesi, J. G.: Immunotherapy of human leukemia with neuraminidase-modified cells. Med. Clinics of North America 60, 539–549 (1976).
Lindenman, J., Klein, P. A.: Immunological aspects of viral oncolysis. Recent advances in cancer research. Berlin: Springer-Verlag, 1967, Vol. IX, p. 66.
Rios, A., Simmons, R. L.: Immunospecific regression of various syngeneic mouse tumors in response to neuraminidase-treated tumor cells. J. Natl. Cancer Inst. 51, 637–644 (1973).
Rios, A., Simmons, R. L.: Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells. Intern. J. Cancer 13, 71–81 (1974).
Sanford, B. H.: An alteration in tumor histocompatability induced by neuraminidase. Transplantation 5, 1273 (1967).
Sedlacek, H. H., Meesmann, H., Seiler, F. R.: Regression of spontaneous mammary tumors in dogs after injection of neuraminidase-treated tumor cells. Int. J. Cancer 15, 409 (1975).
Sethi, K. K., Brandis, H.: Neuraminidase induced loss in the transplantability of murine leukemia L1210 induction of immunoprotection and the transfer of induced immunity to normal DBA/2 mice by serum and peritoneal cells. Br. J. Cancer 27, 106–113 (1973).
Sethi, K. K., Teschner, M.: Neuraminidase induced immunospecific destruction of transplantable experimental tumors. Postepy Hig. Med. Doswialdczaine 28, 103–120 (1974).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1977 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Bekesi, J.G., Holland, J.F. (1977). Active Immunotherapy in Leukemia With Neuraminidase-Modified Leukemic Cells*. In: Mathé, G. (eds) Tactics and Strategy in Cancer Treatment. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 62. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81174-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-81174-6_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81176-0
Online ISBN: 978-3-642-81174-6
eBook Packages: Springer Book Archive